Format

Send to

Choose Destination
J Dermatol. 2015 Jun;42(6):596-601. doi: 10.1111/1346-8138.12845. Epub 2015 Mar 26.

Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients.

Author information

1
Department of Dermatology, Southwest Hospital, Nanjing, China.
2
Department of Epidemiology, College of Preventive Medicine, Third Military Medical University, Chongqing, China.
3
Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, China.
4
Department of Dermatology, Affiliated Hospital of Nantong University, Nantong, China.
5
Department of Dermatology, Xiehe Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
6
Department of Dermatology, Tongji Hospital, Tongji Medical College, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
7
Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, China.
8
Department of Dermatology, The Third Xiangya Hospital of Central South University, Changsha, China.
9
Department of Dermatology, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, China.
10
Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.

Abstract

The objective of the study is to evaluate the efficacy and safety of oral inosine pranobex as compared with acyclovir in the treatment of recurrent herpes labialis (RHL) and recurrent herpes genitalis (RHG). A multicenter double-blind, double-dummy, randomized, controlled, parallel group trial was conducted in 144 patients with RHL and 144 RHG. Patients were assigned to treatment in one of two groups: (i) inosine pranobex group (active inosine pranobex, 1 g four times daily, and acyclovir placebo); or (ii) acyclovir group (active acyclovir, 200 mg five times daily, and inosine pranobex placebo). The total symptom score (TSS) of patients with RHL did not differ in the inosine pranobex and acyclovir group on the 3rd or 7th day of treatment. There was also no difference in the efficacy rates between the two groups. No difference of TSS was observed between patients with RHG taking inosine pranobex and acyclovir on days 3 or 5 of the treatment, respectively. The short-term clinical recurrence rate of RHG at 3-month follow-up was much lower in the inosine pranobex group than acyclovir group. The incidence of hyperuricemia was higher in the inosine pranobex group than acyclovir group. In conclusion, inosine pranobex was as effective as acyclovir in treating RHL and RHG with significantly greater reduction of the short-term recurrence rate of herpes genitalis at 3-month follow up. Long-term recurrence rates at 6 months or longer remain to be determined. Hyperuricemia should be monitored during the treatment.

KEYWORDS:

acyclovir; clinical trial; inosine pranobex; recurrent herpes genitalis; recurrent herpes labialis

PMID:
25819042
DOI:
10.1111/1346-8138.12845
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center